Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$148.8MCash, Jun 2026
15moCash Runway (est.)
+11%Share Count, 1 Year
Follow VYGR by emailGet an email when VYGR pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about VYGR, unsubscribe in one click. Privacy
📣 What VYGR Says Is Next
H2 2026 · “NBIB-‘223 (Friedreich’s ataxia gene therapy): Voyager’s partner Neurocrine Biosciences has stated that it intends to initiate a clinical trial with NBIB-‘223 in H2 2026, pending successful FDA IND clearance.”
Company press release, Aug 6, 2026 · SEC filing
Q4 2026 · “VY7523 (anti-tau antibody): Voyager expects tau positron emission tomography (PET) imaging efficacy data in Q4 2026 from the ongoing multiple ascending dose (MAD) clinical trial in participants with Alzheimer’s disease (AD).”
Company press release, Aug 6, 2026 · SEC filing
the end of the year · ““We continue to advance our two tau-targeted programs toward potential inflection points in clinical trials for Alzheimer’s disease before the end of the year, with the tau-targeted antibody VY7523 expected to generate tau PET imaging data and the tau-targeted gene therapy VY1706 expected to begin dosing.” Second Quarter 2026 and Recent Highlights”
Company press release, Aug 6, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
💰 Cash Runway & Dilution Risk
VYGR reported $148.8M in cash and short-term investments (as of Jun 30, 2026) and used about $29.9M/quarter in operations, an estimated runway of 14.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:50 · Elevated
Cash runway 15 months +18
ATM program on file since Nov 2025 +15
Shelf registration (S-3, Nov 2025) +10
Share count +11% in a year +7
Recent financing filings on SEC EDGAR:
Nov 10, 2025 · Shelf registration with ATM program, up to $100M · S-3
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for VYGR and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.